Literature DB >> 11815339

Sildenafil induces retinal vasodilatation in healthy subjects.

Mona Pache1, Peter Meyer, Christian Prünte, Selim Orgül, Ines Nuttli, Josef Flammer.   

Abstract

BACKGROUND: The cardiovascular effects of sildenafil (Viagra), a selective inhibitor of phosphodiesterase type 5 (PDE5), have been extensively studied. However, its effect on human retinal arteries and veins has not yet been investigated. The effect of a single dose administration of sildenafil on the retinal vessel diameters of healthy subjects was evaluated.
METHODS: Sildenafil 50 mg was administered to 10 healthy subjects (male:female = 4:6; mean age 31 (SD 6) years). The diameters of retinal arteries and veins were measured by means of a retinal vessel analyser (RVA) immediately before and at 30, 60, 90, and 120 minutes after sildenafil uptake. Blood pressure, heart rate, and intraocular pressure were monitored in parallel.
RESULTS: A significant increase of 5.8% (p<0.001) in both retinal arterial and venous diameters was found 30 minutes after sildenafil uptake. The diameters returned to baseline after 120 minutes. A mild systemic hypotensive response was seen. Changes in heart rate and intraocular pressure were not observed.
CONCLUSION: Sildenafil causes a significant dilatation of retinal arteries and veins in healthy subjects. A possible role for PDE5 in the regulation of retinal blood flow is implicated.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11815339      PMCID: PMC1771001          DOI: 10.1136/bjo.86.2.156

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  20 in total

1.  Sildenafil and ocular perfusion.

Authors:  W E Sponsel; G Paris; S S Sandoval; D K Sanford; J M Harrison; W R Elliott; Y Trigo
Journal:  N Engl J Med       Date:  2000-06-01       Impact factor: 91.245

2.  Sildenafil (Viagra) associated anterior ischemic optic neuropathy.

Authors:  R Egan; H Pomeranz
Journal:  Arch Ophthalmol       Date:  2000-02

3.  Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue.

Authors:  J D Corbin; S H Francis; I H Osterloh
Journal:  Urology       Date:  2000-09-01       Impact factor: 2.649

4.  Branch retinal artery occlusion; another complication of sildenafil.

Authors:  A Tripathi; N P O'Donnell
Journal:  Br J Ophthalmol       Date:  2000-08       Impact factor: 4.638

Review 5.  Regulatory mechanisms in the retinal and choroidal circulation.

Authors:  C Delaey; J Van De Voorde
Journal:  Ophthalmic Res       Date:  2000 Nov-Dec       Impact factor: 2.892

6.  Effect of isosorbide mononitrate on the human optic nerve and choroidal circulations.

Authors:  J E Grunwald; A Iannaccone; J DuPont
Journal:  Br J Ophthalmol       Date:  1999-02       Impact factor: 4.638

7.  Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension.

Authors:  D Abrams; I Schulze-Neick; A G Magee
Journal:  Heart       Date:  2000-08       Impact factor: 5.994

8.  Sildenafil causes a dose- and time-dependent downregulation of phosphodiesterase type 6 expression in the rat retina.

Authors:  C M Gonzalez; T Bervig; C Podlasek; C F Huang; K E McKenna; K T McVary
Journal:  Int J Impot Res       Date:  1999-09       Impact factor: 2.896

9.  Evaluation of the Zeiss retinal vessel analyser.

Authors:  K Polak; G Dorner; B Kiss; E Polska; O Findl; G Rainer; H G Eichler; L Schmetterer
Journal:  Br J Ophthalmol       Date:  2000-11       Impact factor: 4.638

10.  Human retinal hemodynamics following administration of 5-isosorbide mononitrate.

Authors:  A E Iannaccone; J DuPont; J E Grunwald
Journal:  Curr Eye Res       Date:  2000-03       Impact factor: 2.424

View more
  17 in total

1.  Selective blockade of phosphodiesterase types 2, 5 and 9 results in cyclic 3'5' guanosine monophosphate accumulation in retinal pigment epithelium cells.

Authors:  R M H Diederen; E C La Heij; M Markerink-van Ittersum; A Kijlstra; F Hendrikse; J de Vente
Journal:  Br J Ophthalmol       Date:  2006-08-30       Impact factor: 4.638

2.  No evidence for severe retinopathy of prematurity following sildenafil.

Authors:  C M Pierce; A J Petros; A R Fielder
Journal:  Br J Ophthalmol       Date:  2005-02       Impact factor: 4.638

3.  Hypnosis-associated blue-tinted vision: a case report.

Authors:  Ran D Anbar; Aaron D Savedoff
Journal:  BMC Ophthalmol       Date:  2005-12-01       Impact factor: 2.209

4.  Histological, morphometric, protein and gene expression analyses of rat retinas with ischaemia-reperfusion injury model treated with sildenafil citrate.

Authors:  Diogo S Zanoni; Germana A Da Silva; Raaya Ezra-Elia; Márcio Carvalho; Juliany G Quitzan; Ron Ofri; José L Laus; Renee Laufer-Amorim
Journal:  Int J Exp Pathol       Date:  2017-06       Impact factor: 1.925

5.  Visual impairment with possible macular changes after a high dose of sildenafil in a healthy young woman.

Authors:  Yun-Yun Li; Ya-Jie Yu; Xi-Pu Liu; Ning-Pu Liu
Journal:  Int J Ophthalmol       Date:  2018-02-18       Impact factor: 1.779

6.  Measurement of choroidal perfusion and thickness following systemic sildenafil (Viagra(®) ).

Authors:  David Y Kim; Ronald H Silverman; Robison Vernon Paul Chan; Aziz A Khanifar; Mark Rondeau; Harriet Lloyd; Peter Schlegel; Donald Jackson Coleman
Journal:  Acta Ophthalmol       Date:  2012-09-13       Impact factor: 3.761

Review 7.  New treatment options for erectile dysfunction in patients with diabetes mellitus.

Authors:  Ansu Basu; Robert E J Ryder
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Acute effects of sildenafil on Humphrey visual field and intraocular pressure.

Authors:  Sitki Samet Ermis; Umit Ubeyt Inan; Murat Samli; Faruk Ozturk
Journal:  Int Ophthalmol       Date:  2004-03       Impact factor: 2.031

Review 9.  Phosphodiesterase type 5 inhibitors, visual changes, and nonarteritic anterior ischemic optic neuropathy: is there a link?

Authors:  Konstantinos Hatzimouratidis
Journal:  Curr Urol Rep       Date:  2007-11       Impact factor: 3.092

10.  The primary vascular dysregulation syndrome: implications for eye diseases.

Authors:  Josef Flammer; Katarzyna Konieczka; Andreas J Flammer
Journal:  EPMA J       Date:  2013-06-07       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.